Zydus Therapeutics’ NDA for Saroglitazar to treat PBC granted Priority Review by the US
Zydus Therapeutics, a wholly owned subsidiary of Zydus Lifesciences Limited, a global innovation-led health care company, today announced that the US Food and Drug Administration (US FDA) granted Priority Review to the New Drug Application!-->…
Read More...
Read More...